NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control.
Majocchi S, Lloveras P, Nouveau L, Legrand M, Viandier A, Malinge P, Charreton M, Raymond C, Pace EA, Millard BL, Svensson LA, Kelpšas V, Anceriz N, Salgado-Pires S, Daubeuf B, Magistrelli G, Gueneau F, Moine V, Masternak K, Shang L, Fischer N, Ferlin WG.
Majocchi S, et al. Among authors: fischer n.
Cancer Immunol Res. 2025 Jan 6:OF1-OF19. doi: 10.1158/2326-6066.CIR-24-0298. Online ahead of print.
Cancer Immunol Res. 2025.
PMID: 39760515